Barclays Upgrades Beta Bionics (NASDAQ:BBNX) to “Strong-Buy”

Beta Bionics (NASDAQ:BBNX) was upgraded by equities researchers at Barclays to a “strong-buy” rating in a research note issued on Tuesday, Zacks reports.

Several other brokerages also recently commented on BBNX. The Goldman Sachs Group raised their price objective on Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Wells Fargo & Company started coverage on Beta Bionics in a research report on Wednesday, September 23rd. They set an “overweight” rating and a $28.00 price target on the stock. Robert W. Baird boosted their price objective on Beta Bionics from $14.00 to $16.00 and gave the company a “neutral” rating in a research report on Tuesday, September 15th. UBS Group reaffirmed a “buy” rating and issued a $25.00 price target on shares of Beta Bionics in a research note on Tuesday, September 15th. Finally, Truist Financial upped their price target on shares of Beta Bionics from $23.00 to $28.00 and gave the company a “buy” rating in a report on Thursday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $23.50.

Beta Bionics Price Performance

Beta Bionics stock opened at $17.43 on Tuesday. The company’s 50 day simple moving average is $18.66 and its 200 day simple moving average is $14.96. Beta Bionics has a fifty-two week low of $8.80 and a fifty-two week high of $32.71. The firm has a market capitalization of $784.18 million, a price-to-earnings ratio of -10.56 and a beta of 3.39.

Beta Bionics (NASDAQ:BBNX) last issued its earnings results on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. The firm had revenue of $32.01 million during the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. As a group, analysts predict that Beta Bionics will post -2.02 EPS for the current fiscal year.

Insider Activity at Beta Bionics

In related news, insider Mark Hopman sold 30,779 shares of the stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $20.13, for a total transaction of $619,581.27. Following the sale, the insider owned 56,479 shares in the company, valued at approximately $1,136,922.27. This trade represents a 35.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christy Jones sold 6,430 shares of Beta Bionics stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $23.00, for a total transaction of $147,890.00. Following the completion of the transaction, the director directly owned 19,564 shares in the company, valued at $449,972. This trade represents a 24.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 97,697 shares of company stock worth $1,907,034 in the last 90 days. Corporate insiders own 5.30% of the company’s stock.

Institutional Trading of Beta Bionics

Several large investors have recently bought and sold shares of the business. Eventide Asset Management LLC lifted its holdings in shares of Beta Bionics by 0.8% in the fourth quarter. Eventide Asset Management LLC now owns 4,994,728 shares of the company’s stock worth $152,233,000 after acquiring an additional 37,476 shares during the last quarter. BlackRock Inc. acquired a new position in Beta Bionics during the 2nd quarter worth approximately $52,340,000. Eversept Partners LP lifted its stake in Beta Bionics by 108.6% in the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after purchasing an additional 736,576 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Beta Bionics in the 4th quarter valued at approximately $40,437,000. Finally, Perceptive Advisors LLC grew its stake in shares of Beta Bionics by 39.8% during the first quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after buying an additional 240,000 shares during the last quarter.

Beta Bionics News Roundup

Here are the key news stories impacting Beta Bionics this week:

• Neutral Sentiment: Several law firms reminded shareholders that November 3, 2026 is the deadline to seek appointment as lead plaintiff in a proposed class action covering investors who purchased BBNX shares from July 30, 2025, through February 24, 2026. The notices primarily solicit potential claimants and do not represent a new operational development. Rosen Law Firm deadline notice
• Negative Sentiment: Multiple firms, including Hagens Berman, Kaplan Fox, Rosen and others, say the lawsuit alleges Beta Bionics and certain executives minimized the significance of an FDA Form 483 and failed to adequately disclose regulatory concerns involving iLet. The allegations reportedly include more than 18,000 unreported complaints and preceded an FDA Warning Letter becoming public. The claims have not been proven. Hagens Berman Beta Bionics class-action alert
• Negative Sentiment: The legal coverage highlights the severity of the prior selloff: BBNX allegedly fell from a Class Period high near $31.99 to below $9 across several FDA-related disclosures. The continuing stream of law-firm announcements increases headline, litigation and reputational risk, helping explain the stock’s decline and volatility. Levi and Korsinsky investor alert

Beta Bionics Company Profile

Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company’s dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person’s body weight and meal announcements as key inputs.